Akari Therapeutics PLC (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics PLC (NASDAQ:AKTX) was the target of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 209,369 shares, a decrease of 16.1% from the February 12th total of 249,671 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 218,660 shares, the days-to-cover ratio is presently 1.0 days. Based on an average daily trading volume, of 218,660 shares, the days-to-cover ratio is presently 1.0 days. Approximately 0.7% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of equities analysts have commented on AKTX shares. LADENBURG THALM/SH SH started coverage on Akari Therapeutics in a research note on Monday, January 5th. They set a “buy” rating and a $1.00 price objective on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Akari Therapeutics in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $2.53.

Akari Therapeutics Trading Down 9.7%

Shares of NASDAQ:AKTX opened at $0.21 on Tuesday. The company has a fifty day moving average of $0.25 and a 200-day moving average of $0.50. Akari Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.73.

Institutional Trading of Akari Therapeutics

An institutional investor recently bought a new position in Akari Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics at the end of the most recent quarter. 5.06% of the stock is currently owned by institutional investors.

Akari Therapeutics Company Profile

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.